Processa Pharmaceuticals(PCSA)
$1.870.00 (0.00%)
PCSA
Processa Pharmaceuticals financials statements
$1.87
At close:0.00 (0.00%)
Want to see PCSA full AI Analyst Report?
Processa Pharmaceuticals (PCSA) Ratios
329 Followers
Processa Pharmaceuticals Ratios
PCSA's free cash flow for Q2 2026 was $-1.50M. For the 2026 fiscal year, PCSA's free cash flow was increased by $500.00K and operating cash flow was $-2.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.54 | 1.22 | 7.71 | 8.40 | 18.87 |
| Quick Ratio | 2.54 | 1.22 | 7.71 | 8.40 | 18.87 |
| Cash Ratio | 2.48 | 0.78 | 6.44 | 6.51 | 16.99 |
| Solvency Ratio | -6.06 | -7.73 | -13.95 | -23.18 | -10.87 |
| Operating Cash Flow Ratio | -5.09 | -7.34 | -11.04 | -9.62 | -8.98 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 3.43M | $ 340.50K | $ 4.84M | $ 7.24M | $ 17.35M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.02 | 0.03 | 0.03 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.04 | 0.03 | 0.03 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.04 | 0.03 | 0.03 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 1.90 | 1.16 | 1.15 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -28302.15 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -33518.07 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.60 | 2.87 | 7.12 | 2.57 |
| Net Debt to EBITDA | 0.41 | 0.09 | 0.40 | 0.32 | 1.52 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 95.56% |
| EBT Per EBIT | 96.96% | 98.33% | 97.07% | 99.63% | 98.55% |
| Return on Assets (ROA) | -173.59% | -366.96% | -192.19% | -318.15% | -43.18% |
| Return on Equity (ROE) | -243.20% | -698.64% | -222.91% | -367.09% | -44.84% |
| Return on Capital Employed (ROCE) | -250.81% | -710.29% | -226.60% | -361.16% | -47.60% |
| Return on Invested Capital (ROIC) | -250.81% | -680.98% | -222.91% | -357.46% | -45.36% |
| Return on Tangible Assets | -203.41% | -366.96% | -192.19% | -318.15% | -62.08% |
| Earnings Yield | -359.72% | -438.09% | -126.75% | -154.76% | -15.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.70 | -91.87 | -153.70 | -298.12 | -284.52 |
| Free Cash Flow Per Share | -8.70 | -91.90 | -153.75 | -298.12 | -284.52 |
| Dividend Paid and CapEx Coverage Ratio | -2277039.00 | -3466.41 | -2904.66 | -3201714.33 | 0.00 |
| Capital Expenditure Coverage Ratio | -2277039.00 | -3466.41 | -2904.66 | -3201714.33 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | -152.98 | -53.56 | -41.86 | -111.10 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -301.94% | -415.84% | -91.93% | -54.20% | -11.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.28 | -0.23 | -0.79 | -0.65 | -6.57 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.68 | 1.59 | 1.76 | 2.37 | 2.95 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.33 | -0.24 | -1.09 | -1.84 | -8.61 |
| Price-to-Operating Cash Flow Ratio | -0.33 | -0.24 | -1.09 | -1.84 | -8.61 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | -0.00 | 0.01 | 0.09 |
| Enterprise Value Multiple | 0.13 | -0.13 | -0.37 | -0.59 | -5.44 |
| Enterprise Value | -1.77M | 1.59M | 4.22M | 11.45M | 58.65M |
| EV to EBITDA | 0.13 | -0.13 | -0.37 | -0.59 | -5.44 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.16 | -0.14 | -0.52 | -1.19 | -6.73 |
| EV to Operating Cash Flow | 0.16 | -0.14 | -0.52 | -1.19 | -6.73 |
| Tangible Book Value Per Share | 3.39 | 13.86 | 95.10 | 231.87 | 568.83 |
| Shareholders’ Equity Per Share | 4.26 | 13.86 | 95.10 | 231.87 | 831.79 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -10.36 | -96.82 | -211.99 | -851.18 | -372.97 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.96 |
| Interest Burden | 1.00 | 1.00 | 0.97 | 1.35 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.84 | 0.95 | 0.73 | 0.35 | 0.76 |
Currency in USD
